N1-Methylpseudouridine-5′-triphosphate solution (100 mM)
Based on 1 publication(s) in Google Scholar
N1-Methylpseudouridine-5′-triphosphate (1-Methylpseudouridine-5′-triphosphate) is a nucleobase-modified nucleotide, used for synthesizing mRNA with reduced immunogenicity and improved stability.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 1428903-59-6
- Formula: C10H17N2O15P3
- Molecular Weight:498.17
-
Storage:
Solution, -20°C, 2 years
Publications Citing Use of MedChemExpress (MCE) N1-Methylpseudouridine-5′-triphosphate solution (100 mM)
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
N1-Methylpseudouridine-5′-triphosphate is used to synthesize mRNAs with lower immunogenicity and higher stability[1].
Modified mRNAs synthesized from N1-Methylpseudouridine-5′-triphosphate can be delivered to the heart[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1428903-59-6
-
Appearance Liquid
-
Molecular Weight 498.17
-
Formula C10H17N2O15P3
-
Color Colorless to light yellow
-
SMILES
O[C@H]1[C@@H](O)[C@H](C(C(N2)=O)=CN(C)C2=O)O[C@@H]1COP(OP(OP(O)(O)=O)(O)=O)(O)=O
-
Synonyms
1-Methylpseudouridine-5′-triphosphate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, 2 years
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
H2O : ≥ 100 mg/mL (200.73 mM)
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337-344. [Content Brief]
[2]. Sultana N, et al. Optimizing Cardiac Delivery of Modified mRNA. Mol Ther. 2017 Jun 7;25(6):1306-1315. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.0073 mL | 10.0367 mL | 20.0735 mL | 50.1837 mL |
| 5 mM | 0.4015 mL | 2.0073 mL | 4.0147 mL | 10.0367 mL | |
| 10 mM | 0.2007 mL | 1.0037 mL | 2.0073 mL | 5.0184 mL | |
| 15 mM | 0.1338 mL | 0.6691 mL | 1.3382 mL | 3.3456 mL | |
| 20 mM | 0.1004 mL | 0.5018 mL | 1.0037 mL | 2.5092 mL | |
| 25 mM | 0.0803 mL | 0.4015 mL | 0.8029 mL | 2.0073 mL | |
| 30 mM | 0.0669 mL | 0.3346 mL | 0.6691 mL | 1.6728 mL | |
| 40 mM | 0.0502 mL | 0.2509 mL | 0.5018 mL | 1.2546 mL | |
| 50 mM | 0.0401 mL | 0.2007 mL | 0.4015 mL | 1.0037 mL | |
| 60 mM | 0.0335 mL | 0.1673 mL | 0.3346 mL | 0.8364 mL | |
| 80 mM | 0.0251 mL | 0.1255 mL | 0.2509 mL | 0.6273 mL | |
| 100 mM | 0.0201 mL | 0.1004 mL | 0.2007 mL | 0.5018 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.